At the end of 2023, a partnership agreement was signed between Novartis and the Nice University Hospital in the presence of Denis BURGARELLA, Director of Public Relations and Promotion at Nice University Hospital; Eric MONCH, Director of Clinical Research and Innovation; Dr. Patrick MESHAKA, Medical Director France of Novartis; Joumana HUDRY, Market Access, Public Affairs and Institutional Affairs Director of Novartis; Sandra MAHAMADALY, Director of Clinical Operations of Novartis; Professor Christian ROUX (Director of the CRC); and Professor Jean DELLAMONICA, Dean of the Faculty of Medicine.
The agreement aims to develop collaboration in clinical research and therapeutic innovation, targeting research programs of mutual interest.
At Nice University Hospital, about fifteen clinical trials promoted by Novartis are underway with an increasing number of patients included.
These trials cover the fields of cardiology, immunology, dermatology, hematology, and neurology. They particularly concern rare diseases or diseases for which medicine currently has no satisfactory solution. Innovations can thus be offered to eligible patients.
Nice University Hospital has proposed to Novartis to work on this written agreement around a common subject in terms of research and innovations. The goal is to define the collaboration’s axes and implement the optimization processes for Novartis clinical trials, the modalities of interactions, as well as the deployment of mixed working groups by themes, co-led by a representative from each entity.
Expected outcomes:
- Consolidate existing collaborations between teams
- Promote access to therapeutic innovations through the development of new clinical trials
- Pool skills and development opportunities
- Increase the attractiveness of Nice University Hospital in terms of research and innovation
- More firmly anchor the hospital in its territory by developing projects related to the care pathways of patients within the hospital and in the community
Research at Nice University Hospital in numbers:
- Over 1250 ongoing clinical trials and innovative projects
- 24 patents
- Over 1000 scientific publications, 45% of which are published in excellence journals (SIGAPS score: 10589)
Nice University Hospital: A public health institution of reference serving the population of the French Riviera, Nice University Hospital fulfills its missions of care, research, and teaching, guided by the values that drive it: care for and with everyone, excellence, innovation, and openness. The skills of its 9000 employees, combined with a very high level of demand in terms of the quality of care and state-of-the-art equipment, enable it to handle both local emergencies and the most complex cases in the most technical fields. Its involvement in research and innovation through numerous significant clinical trials, its excellence labels, its sixty expert centers, and its reference centers for rare diseases contribute to its reputation.
Health Nice Côte d’Azur
- Obesity: French first at Nice University Hospital
- Team Nice Côte d’Azur at the Van Lanschot Kempen Life Sciences Conference 2026
- Launch of the AZUR Territorial Research Entity to advance clinical research on the French Riviera
- BIO-Europe Spring 2026 : meet with Team Nice Côte d’Azur
- Eurobiomed: more than €300 million secured in 2025 in the Sud and Occitanie regions by Eurobiomed member healthcare companies
- Artificial intelligence: Team Nice Côte d’Azur mobilized for an AI Business Tour and WAICF 2026
- Nice University Hospital signs an international cooperation agreement with Emirates Hospitals Group (Dubai)
- Caranx Medical, a Nice-based cardiac robotics MedTech startup, set to be acquired for €16.6 million
- AVC continues its expansion with a consolidated base in the Côte d’Azur
- New medical governance at CHU de Nice
